Literature DB >> 26578177

Perineural expression of high-mobility group box-1 contributes to long-lasting mechanical hypersensitivity via matrix metalloprotease-9 up-regulation in mice with painful peripheral neuropathy.

Fang Fang Zhang1, Norimitsu Morioka1, Sakura Harano1, Yoki Nakamura1, Keyue Liu1, Masahiro Nishibori2, Kazue Hisaoka-Nakashima1, Yoshihiro Nakata1.   

Abstract

High-mobility group box-1 (HMGB1) has been shown to be critical in the modulation of nociceptive transduction following a peripheral neuropathy. However, the precise role of peripherally expressed HMGB1 in neuropathic pain has yet to be fully elaborated. Following a partial sciatic nerve ligation (PSNL) in mice, a persistent ipsilateral up-regulation of HMGB1 was observed from 3 to 21 days after PSNL, in paralleled with a robust ipsilateral hind paw mechanical hypersensitivity. Increased HMGB1 was detected in both infiltrating macrophages and proliferating Schwann cells in the ipsilateral nerve 14 days following PSNL. Repeated perineural treatment with anti-HMGB1 antibody significantly ameliorated PSNL-induced mechanical hypersensitivity. Several pronociceptive molecules, including matrix metalloprotease-9 (MMP-9), tumor necrosis factor-α, interleukin-1β (IL-1β), and cyclooxygenase-2, were up-regulated in injured sciatic nerve 14 days following PSNL. Repeated perineural treatment with an anti-HMGB1 antibody significantly suppressed expression of MMP-9, but not other pronociceptive molecules. Perineural treatment with a selective MMP-9 inhibitor ameliorated PSNL-induced mechanical hypersensitivity. The current findings demonstrate that the maintenance of the neuropathic state following an injured nerve is dependent on the up-regulation of HMGB1 and MMP-9. Thus, blocking HMGB1 function in sciatic nerve could be a potent therapeutic strategy for the treatment of neuropathic pain. Increased peripheral high-mobility group box-1 (HMGB1) is involved in the modulation of nociceptive transduction following a peripheral neuropathy. Following nerve injury in mice, increased HMGB1 is detected in both infiltrating macrophages and proliferating Schwann cells in the ipsilateral nerve. Repeated perineural treatment with anti-HMGB1 antibody significantly ameliorates nerve injury-induced mechanical hypersensitivity, and suppresses expression of matrix metalloprotease-9 (MMP-9). The findings demonstrate that the maintenance of the neuropathic state following an injury nerve is dependent on the up-regulation of HMGB1 and MMP-9.
© 2015 International Society for Neurochemistry.

Entities:  

Keywords:  Allodynia; HMGB1; MMP-9; anti-HMGB1 monoclonal antibody; sciatic nerve

Year:  2015        PMID: 26578177     DOI: 10.1111/jnc.13434

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

1.  Macrophage-derived HMGB1 as a Pain Mediator in the Early Stage of Acute Pancreatitis in Mice: Targeting RAGE and CXCL12/CXCR4 Axis.

Authors:  Yuhei Irie; Maho Tsubota; Hiroyasu Ishikura; Fumiko Sekiguchi; Yuka Terada; Toshifumi Tsujiuchi; Keyue Liu; Masahiro Nishibori; Atsufumi Kawabata
Journal:  J Neuroimmune Pharmacol       Date:  2017-07-28       Impact factor: 4.147

2.  Neuroprotective Effects of Anti-high Mobility Group Box-1 Monoclonal Antibody Against Methamphetamine-Induced Dopaminergic Neurotoxicity.

Authors:  Kaori Masai; Keita Kuroda; Nami Isooka; Ryo Kikuoka; Shinki Murakami; Sunao Kamimai; Dengli Wang; Keyue Liu; Ikuko Miyazaki; Masahiro Nishibori; Masato Asanuma
Journal:  Neurotox Res       Date:  2021-08-21       Impact factor: 3.911

3.  Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state.

Authors:  Sarah A Woller; Satheesh B Ravula; Fabio C Tucci; Graham Beaton; Maripat Corr; R Rivkah Isseroff; Athena M Soulika; Marianne Chigbrow; Kelly A Eddinger; Tony L Yaksh
Journal:  Brain Behav Immun       Date:  2016-04-01       Impact factor: 7.217

Review 4.  Contemporary views on inflammatory pain mechanisms: TRPing over innate and microglial pathways.

Authors:  Zhonghui Guan; Judith Hellman; Mark Schumacher
Journal:  F1000Res       Date:  2016-09-30

Review 5.  High Mobility Group Box-1: A Missing Link between Diabetes and Its Complications.

Authors:  Han Wu; Zheng Chen; Jun Xie; Li-Na Kang; Lian Wang; Biao Xu
Journal:  Mediators Inflamm       Date:  2016-10-25       Impact factor: 4.711

6.  Anti-high mobility group box-1 (HMGB1) antibody inhibits hemorrhage-induced brain injury and improved neurological deficits in rats.

Authors:  Dengli Wang; Keyue Liu; Hidenori Wake; Kiyoshi Teshigawara; Shuji Mori; Masahiro Nishibori
Journal:  Sci Rep       Date:  2017-04-10       Impact factor: 4.379

7.  Lipopolysaccharide from Rhodobacter sphaeroides (TLR4 antagonist) attenuates hypersensitivity and modulates nociceptive factors.

Authors:  Agnieszka M Jurga; Ewelina Rojewska; Wioletta Makuch; Joanna Mika
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

Review 8.  The Emerging Role of HMGB1 in Neuropathic Pain: A Potential Therapeutic Target for Neuroinflammation.

Authors:  Wenbin Wan; Lan Cao; Ramin Khanabdali; Bill Kalionis; Xiantao Tai; Shijin Xia
Journal:  J Immunol Res       Date:  2016-05-18       Impact factor: 4.818

Review 9.  Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages.

Authors:  Norikazu Kiguchi; Daichi Kobayashi; Fumihiro Saika; Shinsuke Matsuzaki; Shiroh Kishioka
Journal:  Int J Mol Sci       Date:  2017-11-01       Impact factor: 5.923

Review 10.  Targeting Inflammation Driven by HMGB1.

Authors:  Huan Yang; Haichao Wang; Ulf Andersson
Journal:  Front Immunol       Date:  2020-03-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.